Elixinol Wellness and British Cannabis have entered an exclusive distribution agreement for the UK market, starting in December 2021, through which British Cannabis will manufacture and supply the company’s range of CBD supplements and cosmetics.
Given the ongoing developments with the regulatory environment in the UK, Elixinol decided to cease trading in the UK and EU markets in 2021, taking an indirect route to market model by seeking a licensing partner in the UK.
This agreement enables the company’s brand to continue to be distributed in the UK, whilst handing over the UK operations and associated cost. The distributor will be the sole and exclusive licensee for the products for a three-year term.
The companies say their shared aim is to improve revenues across the board, while building on the legacy set by Elixinol’s founders over 10 years ago.
Elixinol Global CEO, Oliver Horn, said: “We are delighted about our partnership with British Cannabis who are the most established manufacturer and distributor of branded and white label CBD products in the UK. British Cannabis’ Canabidol brand is widely distributed in UK pharmacies, demonstrating the company’s credentials and capabilities to build brands in sophisticated retail channels. British Cannabis’ manufacturing capability also allows us to manufacture Elixinol products in the UK and thus create a more efficient supply chain solution. Through the partnership with British Cannabis, UK consumers will now continue to be able to buy their favourite Elixinol products and we are very excited to see the brand continue following many years of building the brand.”
British Cannabis CEO, Tom Whettem, commented “It is an honour to be asked to continue the legacy of Elixinol here in our home market. The prospect of a dynamic partnership between Australia’s leading global CBD range and the UK’s premier manufacturer has excited both myself and our leadership team. The ranges from the companies complement each other in several ways and continuing the legacy of Elixinol galvanises us. With the security of our novel foods dossiers, the potential to take this reinforced portfolio to market makes for a very solid proposition for retailers and provides the CBD supplements consumer with great choices.”
